Clement C Chow, MD
Ophthalmology · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 34
- 8 carriers
- Office
- 1
Offices
1 location · Retinal Diagnostic Center A Medical Corporation · 6 clinicians in this group
Plans that list them
34 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chow’s office at (408) 559-0666 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
34 of 34 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A126226 · Current
Licensed to practise in California · since 2013 · expires 2027-05-31 · University of Wisconsin Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$4,309,747
Medicare paid this office $4,309,747 for 1,302 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, faricimab-svoa, 0.1 mg | 273 | $2,428,553 | None |
| Injection, pegcetacoplan, intravitreal, 1 mg | 60 | $624,399 | None |
| Injection, ranibizumab, 0.1 mg | 141 | $316,261 | None |
| Injection of drug into eye | 466 | $267,738 | $108 |
| Established patient complete exam of visual system | 1,159 | $257,022 | $107 |
See all 18 services
| Injection, faricimab-svoa, 0.1 mg | 273 | $2,428,553 | None |
| Injection, pegcetacoplan, intravitreal, 1 mg | 60 | $624,399 | None |
| Injection, ranibizumab, 0.1 mg | 141 | $316,261 | None |
| Injection of drug into eye | 466 | $267,738 | $108 |
| Established patient complete exam of visual system | 1,159 | $257,022 | $107 |
| Imaging of retina | 1,271 | $138,903 | $36 |
| Injection, aflibercept, 1 mg | 14 | $51,501 | None |
| Established patient problem focused exam of visual system | 223 | $24,315 | $77 |
| New patient visit (45+ min) | 201 | $23,241 | $116 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 18 | $19,103 | $1,061 |
| Compounded drug, not otherwise classified | 75 | $16,281 | None |
| 2d ultrasound scan of eye tissue and structures | 190 | $14,868 | $42 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 70 | $11,036 | $158 |
| Photography of the retina | 145 | $5,207 | $32 |
| Destruction of leaking blood vessels of retina using laser | 11 | $3,268 | $297 |
| Photocoagulation treatment to prevent detachment of retina | 13 | $3,148 | $225 |
| Removal of recurring cataract in lens capsule by stab incision | 12 | $3,148 | $262 |
| Return visit (30+ min) | 12 | $1,189 | $91 |
Procedures Medicare counted
| Cataract surgery | 30 | More than 53% of doctors who do this |
Who their Medicare patients are
1,302 Original Medicare patients in 2024. Average age 77 · Under 65 5% · 85 and older 21% · Women 56% · Also on Medicaid 28% · Health risk score 1.50. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 43% · Chronic kidney disease 26% · Coronary heart disease 24% · Atrial fibrillation 18% · Heart failure 17% · Cancer 14% · Depression 14% · COPD 9% · Stroke 8% · Dementia 7%.
The office billed $14,727,931, Medicare allowed $5,509,646 and paid $4,309,747; for 109,848 services of 49 kinds; $3,486,073 of it was for drugs given in the office and $823,674 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,302 | 109,848 | 77 | 1.50 | $14,727,931 | $4,309,747 |
| 2023 | 1,363 | 82,153 | 76 | 1.41 | $13,389,013 | $3,907,824 |
| 2022 | 1,093 | 20,013 | 76 | 1.52 | $8,185,602 | $2,356,663 |
| 2021 | 942 | 10,686 | 76 | 1.57 | $6,295,382 | $1,890,836 |
| 2020 | 856 | 9,953 | 75 | 1.71 | $5,486,799 | $1,631,111 |
| 2019 | 974 | 8,911 | 76 | 1.61 | $4,659,630 | $1,298,190 |
| 2018 | 916 | 7,823 | 75 | 1.58 | $3,739,082 | $1,008,636 |
| 2017 | 809 | 7,169 | 75 | 1.57 | $3,133,932 | $769,481 |
| 2016 | 637 | 5,650 | 74 | 1.53 | $2,581,593 | $620,995 |
| 2015 | 571 | 4,617 | 75 | 1.55 | $2,172,745 | $566,077 |
| 2014 | 438 | 3,651 | 74 | 1.43 | $1,762,531 | $455,307 |
| 2013 | 264 | 1,013 | 71 | 1.59 | $674,845 | $155,690 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 23 services
| Injection, faricimab-svoa, 0.1 mg | 199 | $1,927,026 | None |
| Injection, ranibizumab, 0.1 mg | 181 | $508,727 | None |
| Injection, aflibercept, 1 mg | 79 | $323,102 | None |
| Injection of drug into eye | 453 | $255,910 | $109 |
| Established patient complete exam of visual system | 1,125 | $254,183 | $112 |
| Imaging of retina | 1,333 | $144,266 | $37 |
| Unclassified drugs | 30 | $115,325 | None |
| Injection, pegcetacoplan, intravitreal, 1 mg | 29 | $90,271 | None |
| Established patient problem focused exam of visual system | 308 | $39,360 | $78 |
| New patient visit (45+ min) | 285 | $37,760 | $132 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 24 | $28,914 | $1,112 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 12 | $28,817 | None |
| Compounded drug, not otherwise classified | 105 | $24,759 | None |
| 2d ultrasound scan of eye tissue and structures | 223 | $18,148 | $43 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 99 | $13,793 | $138 |
| Destruction of leaking blood vessels of retina using laser | 18 | $8,486 | $369 |
| Photography of the retina | 182 | $7,084 | $34 |
| Photocoagulation treatment to prevent detachment of retina | 22 | $6,607 | $220 |
| New patient visit (60+ min) | 24 | $4,120 | $172 |
| Long return visit (40+ min) | 12 | $1,424 | $119 |
| Return visit (30+ min) | 13 | $1,085 | $83 |
| Exam of visual field with extended testing | 11 | $691 | $58 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $109 | None |
2022: 18 services
| Injection, aflibercept, 1 mg | 124 | $776,760 | None |
| Injection, ranibizumab, 0.1 mg | 128 | $498,586 | None |
| Injection, faricimab-svoa, 0.1 mg | 72 | $248,877 | None |
| Injection of drug into eye | 345 | $171,521 | $107 |
| Established patient complete exam of visual system | 856 | $165,103 | $108 |
| Unclassified biologics | 45 | $151,193 | None |
| Imaging of retina | 1,055 | $103,342 | $36 |
| Established patient problem focused exam of visual system | 289 | $61,926 | $79 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 13 | $29,804 | None |
| New patient visit (45+ min) | 232 | $29,189 | $126 |
| Compounded drug, not otherwise classified | 103 | $23,120 | None |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 13 | $16,253 | $1,084 |
| 2d ultrasound scan of eye tissue and structures | 166 | $14,326 | $44 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 88 | $11,157 | $127 |
| Photocoagulation treatment to prevent detachment of retina | 18 | $5,166 | $235 |
| Photography of the retina | 114 | $4,051 | $33 |
| New patient visit (60+ min) | 21 | $3,332 | $159 |
| Extended exam of the back part of the eye with retinal drawing | 16 | $377 | $24 |
2021: 18 services
| Injection, aflibercept, 1 mg | 102 | $703,484 | None |
| Injection, ranibizumab, 0.1 mg | 110 | $565,634 | None |
| Established patient complete exam of visual system | 750 | $149,384 | $109 |
| Injection of drug into eye | 292 | $142,470 | $108 |
| Imaging of retina | 874 | $87,969 | $38 |
| Established patient problem focused exam of visual system | 278 | $60,290 | $85 |
| New patient visit (45+ min) | 188 | $25,596 | $136 |
| Compounded drug, not otherwise classified | 91 | $21,943 | None |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 14 | $15,748 | $1,125 |
| Photocoagulation treatment to prevent detachment of retina | 20 | $12,312 | $513 |
| 2d ultrasound scan of eye tissue and structures | 145 | $12,069 | $46 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 96 | $11,483 | $120 |
| Destruction of leaking blood vessels of retina using laser | 20 | $8,377 | $322 |
| Photography of the retina | 237 | $8,066 | $33 |
| Removal of eye fluid | 13 | $2,307 | $110 |
| Injection, bevacizumab, 10 mg | 23 | $1,715 | None |
| Return visit (30+ min) | 14 | $1,084 | $77 |
| Exam of visual field with extended testing | 15 | $910 | $61 |
2020: 17 services
| Injection, aflibercept, 1 mg | 89 | $563,747 | None |
| Injection, ranibizumab, 0.1 mg | 112 | $486,893 | None |
| Established patient complete exam of visual system | 689 | $148,539 | $111 |
| Injection of drug into eye | 291 | $114,924 | $93 |
| Imaging of retina | 712 | $69,694 | $38 |
| Established patient problem focused exam of visual system | 256 | $46,016 | $82 |
| Compounded drug, not otherwise classified | 121 | $27,532 | None |
| New patient visit (45+ min) | 159 | $21,324 | $134 |
| Photography of the retina | 432 | $20,710 | $41 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 15 | $15,824 | $1,055 |
| 2d ultrasound scan of eye tissue and structures | 137 | $11,351 | $50 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 97 | $10,168 | $103 |
| Destruction of leaking blood vessels of retina using laser | 22 | $8,761 | $324 |
| Removal of eye fluid | 16 | $5,203 | $113 |
| Injection, bevacizumab, 10 mg | 21 | $1,590 | None |
| Return visit (30+ min) | 15 | $1,406 | $94 |
| Exam of visual field with extended testing | 11 | $909 | $65 |
2019: 21 services
| Injection, aflibercept, 1 mg | 83 | $445,281 | None |
| Injection, ranibizumab, 0.1 mg | 49 | $225,535 | None |
| Established patient complete exam of visual system | 779 | $169,567 | $109 |
| Injection of drug into eye | 266 | $98,930 | $92 |
| Imaging of retina | 849 | $74,771 | $37 |
| Established patient problem focused exam of visual system | 286 | $40,953 | $81 |
| New patient visit (45+ min) | 229 | $30,450 | $133 |
| Injection, bevacizumab, 10 mg | 140 | $28,199 | None |
| Photography of the retina | 483 | $26,469 | $47 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 15 | $16,723 | $1,115 |
| 2d ultrasound scan of eye tissue and structures | 165 | $15,384 | $57 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 141 | $12,964 | $90 |
| Photocoagulation treatment to prevent detachment of retina | 20 | $12,129 | $505 |
| Destruction of growth of retina using a laser | 15 | $10,317 | $491 |
| Destruction of leaking blood vessels of retina using laser | 21 | $8,917 | $318 |
| Compounded drug, not otherwise classified | 81 | $7,444 | None |
| Return visit (30+ min) | 42 | $3,607 | $80 |
| Removal of eye fluid | 13 | $2,437 | $111 |
| Long return visit (40+ min) | 18 | $1,981 | $110 |
| Exam of visual field with extended testing | 17 | $1,017 | $60 |
| Examination of eye by ophthalmoscope with retinal drawing | 22 | $925 | $26 |
2018: 20 services
| Injection, aflibercept, 1 mg | 59 | $312,256 | None |
| Injection, ranibizumab, 0.1 mg | 36 | $150,941 | None |
| Established patient complete exam of visual system | 665 | $124,364 | $103 |
| Injection of drug into eye | 213 | $74,051 | $91 |
| Imaging of retina | 772 | $66,611 | $37 |
| Established patient problem focused exam of visual system | 273 | $35,833 | $77 |
| New patient visit (45+ min) | 278 | $35,548 | $128 |
| Injection, bevacizumab, 10 mg | 144 | $28,832 | None |
| Photography of the retina | 356 | $20,327 | $51 |
| 2d ultrasound scan of eye tissue and structures | 150 | $18,431 | $70 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 13 | $14,858 | $1,143 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 12 | $14,134 | $1,087 |
| Destruction of growth of retina using a laser | 22 | $13,606 | $469 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 157 | $12,669 | $81 |
| Destruction of leaking blood vessels of retina using laser | 21 | $10,133 | $317 |
| Photocoagulation treatment to prevent detachment of retina | 17 | $9,346 | $492 |
| Return visit (30+ min) | 55 | $5,630 | $94 |
| Removal of eye fluid | 15 | $3,413 | $110 |
| Long return visit (40+ min) | 15 | $2,098 | $131 |
| Exam of visual field with extended testing | 12 | $577 | $48 |
2017: 25 services
| Injection, aflibercept, 1 mg | 50 | $200,846 | None |
| Established patient complete exam of visual system | 559 | $106,422 | $99 |
| Injection of drug into eye | 207 | $66,217 | $89 |
| Injection, ranibizumab, 0.1 mg | 11 | $58,813 | None |
| Imaging of retina | 670 | $55,941 | $35 |
| Injection, bevacizumab, 10 mg | 163 | $30,284 | None |
| New patient visit (45+ min) | 235 | $29,936 | $127 |
| Established patient problem focused exam of visual system | 229 | $27,310 | $76 |
| Photography of the retina | 342 | $23,488 | $61 |
| 2d ultrasound scan of eye tissue and structures | 131 | $19,583 | $83 |
| Destruction of growth of retina using a laser | 23 | $15,186 | $460 |
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 11 | $14,029 | $1,169 |
| Destruction of leaking blood vessels of retina using laser | 31 | $13,552 | $301 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 14 | $12,821 | $916 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 11 | $12,026 | $1,093 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 163 | $11,839 | $72 |
| Return visit (30+ min) | 90 | $8,773 | $91 |
| Photocoagulation treatment to prevent detachment of retina | 16 | $8,070 | $475 |
| New patient visit (60+ min) | 28 | $4,532 | $162 |
| Injection, triamcinolone acetonide, preservative free, 1 mg | 15 | $2,532 | None |
| Removal of eye fluid | 19 | $2,467 | $107 |
| Long return visit (40+ min) | 14 | $1,388 | $99 |
| Exam of visual field with extended testing | 11 | $679 | $57 |
| Examination of eye by ophthalmoscope with retinal drawing | 18 | $667 | $24 |
| Examination of eye by ophthalmoscope with retinal drawing | 14 | $537 | $22 |
2016: 19 services
| Injection, aflibercept, 1 mg | 39 | $135,285 | None |
| Established patient complete exam of visual system | 479 | $110,331 | $101 |
| Imaging of retina | 528 | $50,898 | $39 |
| Injection of drug into eye | 162 | $50,583 | $90 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 179 | $35,998 | $98 |
| Injection, bevacizumab, 10 mg | 132 | $24,146 | None |
| New patient visit (45+ min) | 185 | $24,058 | $130 |
| Photography of the retina | 278 | $20,766 | $67 |
| Destruction of leaking blood vessels of retina using laser | 31 | $14,370 | $312 |
| 2d ultrasound scan of eye tissue and structures | 93 | $13,958 | $83 |
| Photocoagulation treatment to prevent detachment of retina | 20 | $13,255 | $457 |
| Removal of membrane of retina | 12 | $13,021 | $1,085 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 12 | $12,993 | $1,083 |
| Established patient problem focused exam of visual system | 103 | $10,358 | $70 |
| Destruction of growth of retina using a laser | 14 | $7,112 | $474 |
| New patient visit (60+ min) | 32 | $5,113 | $160 |
| Long return visit (40+ min) | 12 | $1,455 | $121 |
| Examination of eye by ophthalmoscope with retinal drawing | 24 | $1,001 | $23 |
| Examination of eye by ophthalmoscope with retinal drawing | 11 | $461 | $18 |
2015: 21 services
| Injection, aflibercept, 1 mg | 28 | $113,771 | None |
| Established patient complete exam of visual system | 302 | $60,309 | $100 |
| Injection, ranibizumab, 0.1 mg | 13 | $42,641 | None |
| Imaging of retina | 442 | $40,558 | $39 |
| Injection of drug into eye | 134 | $35,640 | $86 |
| Destruction of leaking blood vessels of retina using laser | 26 | $35,061 | $877 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 148 | $29,070 | $96 |
| New patient visit (45+ min) | 211 | $27,431 | $130 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 14 | $20,925 | $1,495 |
| Established patient problem focused exam of visual system | 202 | $20,779 | $73 |
| Injection, bevacizumab, 10 mg | 108 | $15,486 | None |
| Photography of the retina | 187 | $13,444 | $66 |
| Photocoagulation treatment to prevent detachment of retina | 22 | $11,412 | $476 |
| 2d ultrasound scan of eye tissue and structures | 70 | $8,844 | $83 |
| Destruction of growth of retina using a laser | 12 | $7,537 | $471 |
| New patient visit (60+ min) | 41 | $6,863 | $167 |
| Removal of eye fluid | 19 | $3,005 | $100 |
| Examination of eye by ophthalmoscope with retinal drawing | 40 | $1,590 | $24 |
| Examination of eye by ophthalmoscope with retinal drawing | 37 | $1,318 | $21 |
| New patient visit (30+ min) | 14 | $1,214 | $87 |
| Exam of visual field with extended testing | 14 | $726 | $52 |
2014: 20 services
| Injection, aflibercept, 1 mg | 14 | $75,334 | None |
| Established patient complete exam of visual system | 238 | $52,340 | $106 |
| Imaging of retina | 325 | $30,594 | $40 |
| New patient visit (45+ min) | 229 | $28,969 | $127 |
| Injection of drug into eye | 95 | $27,791 | $85 |
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 11 | $23,762 | $1,584 |
| Destruction of leaking blood vessels of retina using laser | 20 | $21,934 | $844 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 105 | $20,276 | $95 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 11 | $15,643 | $1,422 |
| Injection, bevacizumab, 10 mg | 78 | $12,019 | None |
| Photocoagulation treatment to prevent detachment of retina | 21 | $10,909 | $474 |
| 2d ultrasound scan of eye tissue and structures | 74 | $9,781 | $84 |
| Destruction of growth of retina using a laser | 14 | $9,562 | $455 |
| Established patient problem focused exam of visual system | 82 | $8,825 | $74 |
| Photography of the retina | 110 | $7,710 | $65 |
| New patient visit (60+ min) | 25 | $4,330 | $173 |
| Examination of eye by ophthalmoscope with retinal drawing | 64 | $4,085 | $22 |
| Removal of eye fluid | 20 | $4,080 | $107 |
| Examination of eye by ophthalmoscope with retinal drawing | 63 | $2,666 | $25 |
| Exam of the internal drainage system of eye | 12 | $529 | $24 |
2013: 12 services
| New patient visit (45+ min) | 122 | $16,579 | $136 |
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 18 | $13,321 | $666 |
| Injection of drug into eye | 45 | $7,696 | $88 |
| Established patient problem focused exam of visual system | 63 | $7,022 | $75 |
| Imaging of retina | 123 | $6,696 | $40 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 32 | $6,068 | $95 |
| Established patient complete exam of visual system | 27 | $3,305 | $110 |
| Injection, bevacizumab, 10 mg | 32 | $3,091 | None |
| 2d ultrasound scan of eye tissue and structures | 26 | $3,055 | $85 |
| Photography of the retina | 39 | $2,556 | $64 |
| Examination of eye by ophthalmoscope with retinal drawing | 20 | $893 | $25 |
| Short return visit (20+ min) | 16 | $722 | $40 |
Medicaid work
$549,807 in 2024
Medicaid paid $549,807 for 5,065 billed services this clinician did in 2024, up to 181 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Injection, faricimab-svoa, 0.1 mg | 383 | $371,548 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 1,066 | $68,555 |
| Ranibizumab injection | 116 | $26,521 |
| Return visit (30+ min) | 255 | $19,122 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,443 | $18,636 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 678 | $14,230 |
| Injection, bevacizumab, 10 mg | 404 | $13,450 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 190 | $9,357 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 253 | $3,639 |
| OPH US DX B-SCAN | 247 | $3,462 |
| New patient visit (45+ min) | 30 | $1,287 |
| 2024 | 5,065 | 11 | 181 | $549,807 |
| 2023 | 7,218 | 13 | 194 | $683,319 |
| 2022 | 4,663 | 12 | 161 | $286,232 |
| 2021 | 3,848 | 9 | 126 | $167,210 |
| 2020 | 3,602 | 11 | 92 | $148,467 |
| 2019 | 4,082 | 10 | 104 | $139,276 |
| 2018 | 3,793 | 18 | 101 | $135,378 |
See the largest Medicaid services in earlier years
2023
| Aflibercept injection | 211 | $200,385 |
| Injection, faricimab-svoa, 0.1 mg | 214 | $196,861 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 1,407 | $98,563 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 1,011 | $39,299 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 2,139 | $32,429 |
| Ranibizumab injection | 88 | $26,054 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 423 | $24,328 |
| Injection, bevacizumab, 10 mg | 588 | $23,091 |
| New patient visit (45+ min) | 221 | $17,251 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 357 | $8,743 |
| Return visit (30+ min) | 147 | $7,724 |
| OPH US DX B-SCAN | 398 | $7,705 |
2022
| Aflibercept injection | 201 | $124,650 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 839 | $54,506 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 529 | $29,322 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,424 | $21,771 |
| Injection, bevacizumab, 10 mg | 372 | $15,973 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 666 | $14,929 |
| New patient visit (45+ min) | 136 | $9,119 |
| Ranibizumab injection | 25 | $8,034 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 161 | $4,105 |
| OPH US DX B-SCAN | 284 | $3,453 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 12 | $351 |
| Compounded drug, not otherwise classified | 14 | $19 |
2021
| Aflibercept injection | 53 | $45,610 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 673 | $40,909 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 504 | $27,968 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,133 | $15,520 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 640 | $13,365 |
| Injection, bevacizumab, 10 mg | 314 | $11,635 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 256 | $6,064 |
| OPH US DX B-SCAN | 231 | $3,939 |
| New patient visit (45+ min) | 44 | $2,200 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 715 | $37,330 |
| Aflibercept injection | 27 | $26,571 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 473 | $25,617 |
| Injection, bevacizumab, 10 mg | 402 | $16,612 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 919 | $13,534 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 320 | $10,996 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 512 | $8,351 |
| Ranibizumab injection | 12 | $4,638 |
| OPH US DX B-SCAN | 168 | $3,569 |
| New patient visit (45+ min) | 28 | $1,103 |
| Compounded drug, not otherwise classified | 26 | $146 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 673 | $37,377 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 523 | $33,367 |
| Injection, bevacizumab, 10 mg | 531 | $21,332 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,090 | $16,801 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 360 | $11,997 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 627 | $8,376 |
| New patient visit (45+ min) | 100 | $6,621 |
| OPH US DX B-SCAN | 127 | $1,995 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 32 | $1,302 |
| Compounded drug, not otherwise classified | 19 | $108 |
2018
| Intravitreal injection of a pharmacologic agent (separate procedure) | 450 | $38,349 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 457 | $29,716 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 989 | $20,171 |
| Injection, bevacizumab, 10 mg | 439 | $19,041 |
| New patient visit (45+ min) | 149 | $13,273 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 404 | $7,857 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 177 | $5,482 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 26 | $765 |
| OPH US DX B-SCAN | 46 | $723 |
| TOBACCO NON-USER | 151 | $0 |
| Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; with evidence of retinopathy (DM) | 101 | $0 |
| 7 standard field stereoscopic retinal photos with interpretation by an ophthalmologist or optometrist documented and reviewed; with evidence of retinopathy (DM) | 101 | $0 |
Drugs they prescribed that Part D paid
$36,434
Pharmacies billed $36,434 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 532) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
359 generic and 173 brand-name prescriptions · $36,434 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cyclosporine | 14 | $4,979 | $356 |
| Prednisolone Acetate | 78 | $2,993 | $38 |
| Difluprednate | 22 | $1,569 | $71 |
| Ketorolac Tromethamine | 47 | $952 | $20 |
| Brimonidine | 83 | $847 | $10 |
See all 11 drugs
| Cyclosporine | 14 | $4,979 | $356 |
| Prednisolone Acetate | 78 | $2,993 | $38 |
| Difluprednate | 22 | $1,569 | $71 |
| Ketorolac Tromethamine | 47 | $952 | $20 |
| Brimonidine | 83 | $847 | $10 |
| Dorzolamide-Timolol | 73 | $803 | $11 |
| Latanoprost | 62 | $640 | $10 |
| Timolol Maleate | 35 | $223 | $6 |
| Dorzolamide | 27 | $217 | $8 |
| Neomycin-Polymyxin-Dexameth | 18 | $165 | $9 |
| Erythromycin | 15 | $133 | $9 |
Year by year
| 2024 | 532 | 139 | 0% (0) | 33% | $36,434 |
| 2023 | 605 | 152 | 0% (0) | 36% | $39,325 |
| 2022 | 494 | 132 | 0% (0) | 34% | $28,308 |
| 2021 | 515 | 118 | 0% (0) | 39% | $29,620 |
| 2020 | 378 | 104 | None | 40% | $24,108 |
| 2019 | 460 | 108 | None | 43% | $39,512 |
| 2018 | 541 | 148 | None | 46% | $36,909 |
| 2017 | 375 | 123 | 0% (0) | 54% | $28,822 |
| 2016 | 340 | 103 | None | 55% | $23,934 |
| 2015 | 309 | 100 | None | 58% | $25,294 |
| 2014 | 274 | 96 | None | 55% | $21,498 |
| 2013 | 216 | 66 | None | 51% | $14,152 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Prednisolone Acetate | 111 | $4,312 | $39 |
| Dorzolamide-Timolol | 99 | $2,397 | $24 |
| Brimonidine | 98 | $2,272 | $23 |
| Difluprednate | 11 | $1,717 | $156 |
| Latanoprost | 68 | $1,585 | $23 |
| Ketorolac Tromethamine | 38 | $1,251 | $33 |
| Dorzolamide-Timolol | 11 | $843 | $77 |
| Atropine Sulfate | 14 | $723 | $52 |
| Timolol Maleate | 41 | $471 | $11 |
| Dorzolamide | 11 | $422 | $38 |
| Neomycin-Polymyxin-Dexameth | 20 | $364 | $18 |
| Diclofenac | 11 | $128 | $12 |
2022: 11 drugs
| Restasis | 11 | $7,713 | $701 |
| Prednisolone Acetate | 62 | $3,042 | $49 |
| Difluprednate | 13 | $1,926 | $148 |
| Dorzolamide-Timolol | 61 | $1,747 | $29 |
| Latanoprost | 80 | $1,455 | $18 |
| Ketorolac Tromethamine | 42 | $1,267 | $30 |
| Brimonidine | 74 | $973 | $13 |
| Olopatadine | 21 | $684 | $33 |
| Dorzolamide | 17 | $406 | $24 |
| Timolol Maleate | 40 | $345 | $9 |
| Neomycin-Polymyxin-Dexameth | 15 | $223 | $15 |
2021: 11 drugs
| Restasis | 11 | $7,159 | $651 |
| Prednisolone Acetate | 70 | $3,467 | $50 |
| Bromfenac | 12 | $2,358 | $196 |
| Latanoprost | 92 | $1,820 | $20 |
| Brimonidine | 69 | $1,730 | $25 |
| Dorzolamide-Timolol | 63 | $1,716 | $27 |
| Olopatadine | 18 | $608 | $34 |
| Dorzolamide | 24 | $590 | $25 |
| Ketorolac Tromethamine | 21 | $552 | $26 |
| Neomycin-Polymyxin-Dexameth | 31 | $529 | $17 |
| Timolol Maleate | 38 | $340 | $9 |
2020: 11 drugs
| Durezol | 15 | $3,255 | $217 |
| Prednisolone Acetate | 62 | $2,522 | $41 |
| Dorzolamide-Timolol | 52 | $1,972 | $38 |
| Bromfenac | 11 | $1,697 | $154 |
| Brimonidine | 56 | $1,391 | $25 |
| Ketorolac Tromethamine | 27 | $970 | $36 |
| Latanoprost | 41 | $833 | $20 |
| Azelastine | 11 | $450 | $41 |
| Olopatadine | 11 | $415 | $38 |
| Dorzolamide | 12 | $410 | $34 |
| Timolol Maleate | 20 | $144 | $7 |
2019: 12 drugs
| Durezol | 25 | $5,106 | $204 |
| Pazeo | 13 | $4,032 | $310 |
| Olopatadine | 44 | $3,739 | $85 |
| Alphagan P | 17 | $2,987 | $176 |
| Prednisolone Acetate | 55 | $2,538 | $46 |
| Combigan | 11 | $1,950 | $177 |
| Dorzolamide-Timolol | 35 | $1,607 | $46 |
| Ketorolac Tromethamine | 44 | $1,416 | $32 |
| Brimonidine | 40 | $829 | $21 |
| Latanoprost | 59 | $659 | $11 |
| Dorzolamide | 16 | $464 | $29 |
| Timolol Maleate | 31 | $246 | $8 |
2018: 13 drugs
| Azopt | 22 | $6,428 | $292 |
| Olopatadine | 43 | $4,323 | $101 |
| Tobramycin-Dexamethasone | 53 | $4,293 | $81 |
| Travatan Z | 12 | $3,617 | $301 |
| Prednisolone Acetate | 75 | $3,518 | $47 |
| Ketorolac Tromethamine | 53 | $2,537 | $48 |
| Durezol | 13 | $2,291 | $176 |
| Combigan | 11 | $2,157 | $196 |
| Brimonidine | 35 | $1,458 | $42 |
| Dorzolamide-Timolol | 41 | $827 | $20 |
| Latanoprost | 76 | $782 | $10 |
| Timolol Maleate | 48 | $534 | $11 |
| Dorzolamide | 11 | $183 | $17 |
2017: 9 drugs
| Tobramycin-Dexamethasone | 59 | $5,405 | $92 |
| Travatan Z | 19 | $4,547 | $239 |
| Prednisolone Acetate | 66 | $3,304 | $50 |
| Olopatadine | 20 | $2,278 | $114 |
| Ketorolac Tromethamine | 34 | $1,588 | $47 |
| Brimonidine | 24 | $1,051 | $44 |
| Dorzolamide-Timolol | 25 | $615 | $25 |
| Latanoprost | 37 | $446 | $12 |
| Timolol Maleate | 17 | $97 | $6 |
2016: 7 drugs
| Tobramycin-Dexamethasone | 60 | $7,031 | $117 |
| Prednisolone Acetate | 66 | $3,252 | $49 |
| Brimonidine | 24 | $2,629 | $110 |
| Durezol | 14 | $2,156 | $154 |
| Ketorolac Tromethamine | 57 | $2,003 | $35 |
| Dorzolamide-Timolol | 38 | $583 | $15 |
| Latanoprost | 15 | $171 | $11 |
2015: 7 drugs
| Tobramycin-Dexamethasone | 45 | $5,385 | $120 |
| Prednisolone Acetate | 67 | $3,914 | $58 |
| Pataday | 18 | $2,886 | $160 |
| Brimonidine | 30 | $2,721 | $91 |
| Ketorolac Tromethamine | 26 | $1,090 | $42 |
| Dorzolamide-Timolol | 30 | $522 | $17 |
| Latanoprost | 13 | $156 | $12 |
2014: 6 drugs
| Tobramycin-Dexamethasone | 70 | $10,262 | $147 |
| Prednisolone Acetate | 67 | $4,080 | $61 |
| Brimonidine | 16 | $793 | $50 |
| Dorzolamide-Timolol | 18 | $504 | $28 |
| Latanoprost | 25 | $367 | $15 |
| Ketorolac Tromethamine | 12 | $330 | $27 |
2013: 5 drugs
| Tobramycin-Dexamethasone | 31 | $3,919 | $126 |
| Brimonidine | 27 | $1,679 | $62 |
| Dorzolamide-Timolol | 29 | $1,181 | $41 |
| Prednisolone Acetate | 42 | $935 | $22 |
| Latanoprost | 15 | $401 | $27 |
Money from drug and device companies
$1,322 in 2025
| 2025 | 9 | 40 | None | $1,322 |
| 2024 | 10 | 42 | None | $1,620 |
| 2023 | 12 | 32 | None | $1,593 |
| 2022 | 7 | 13 | None | $663 |
| 2021 | 3 | 8 | None | $353 |
| 2020 | 4 | 9 | None | $315 |
| 2019 | 9 | 17 | None | $742 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Pharmaceuticals | Eylea Hd | $281 | 2 payments
|
| Apellis Pharmaceuticals | Syfovre | $268 | 13 payments
|
| Genentech USA | Vabysmo | $264 | 8 payments
|
| Astellas Pharma US | Izervay | $148 | 6 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $147 | 4 payments
|
| ANI Pharmaceuticals | Iluvien | $90 | 3 payments
|
See all 40 published payments
| Regeneron Pharmaceuticals | Meals · 2025-12-04 | Eylea Hd | $131 |
| ANI Pharmaceuticals | Meals · 2025-12-02 | Iluvien | $34 |
| Regeneron Healthcare Solutions | Meals · 2025-11-21 | Eylea Hd | $38 |
| Genentech USA | Meals · 2025-11-20 | Vabysmo | $29 |
| Astellas Pharma US | Meals · 2025-11-19 | Izervay | $20 |
| Apellis Pharmaceuticals | Meals · 2025-11-07 | Syfovre | $29 |
| Astellas Pharma US | Meals · 2025-11-05 | Izervay | $6 |
| Genentech USA | Meals · 2025-10-14 | Vabysmo | $35 |
| Apellis Pharmaceuticals | Meals · 2025-09-19 | Syfovre | $8 |
| Apellis Pharmaceuticals | Meals · 2025-09-19 | Syfovre | $13 |
| ANI Pharmaceuticals | Meals · 2025-09-09 | Iluvien | $28 |
| Genentech USA | Meals · 2025-09-05 | Vabysmo | $31 |
| Mallinckrodt Hospital Products | Meals · 2025-08-29 | Acthar | $38 |
| Apellis Pharmaceuticals | Meals · 2025-08-26 | Syfovre | $27 |
| Regeneron Healthcare Solutions | Meals · 2025-07-30 | Eylea Hd | $33 |
| Amgen | Meals · 2025-07-25 | Tepezza | $30 |
| Apellis Pharmaceuticals | Meals · 2025-07-19 | Syfovre | $5 |
| Apellis Pharmaceuticals | Meals · 2025-07-18 | Syfovre | $5 |
| Apellis Pharmaceuticals | Meals · 2025-07-18 | Syfovre | $20 |
| Apellis Pharmaceuticals | Meals · 2025-07-17 | Syfovre | $20 |
| Genentech USA | Meals · 2025-07-10 | Vabysmo | $34 |
| Astellas Pharma US | Meals · 2025-07-09 | Izervay | $28 |
| Mallinckrodt Hospital Products | Meals · 2025-07-01 | Acthar | $31 |
| Apellis Pharmaceuticals | Meals · 2025-06-13 | Syfovre | $28 |
| ANI Pharmaceuticals | Meals · 2025-06-03 | Yutiq | $28 |
| Genentech USA | Meals · 2025-05-23 | Vabysmo | $35 |
| Abbvie | Meals · 2025-05-07 | Ozurdex | $26 |
| Regeneron Healthcare Solutions | Meals · 2025-05-06 | Eylea Hd | $40 |
| Regeneron Pharmaceuticals | Meals · 2025-04-16 | None | $150 |
| Apellis Pharmaceuticals | Meals · 2025-04-10 | Syfovre | $27 |
| Genentech USA | Meals · 2025-04-04 | Vabysmo | $31 |
| Apellis Pharmaceuticals | Meals · 2025-04-01 | Syfovre | $29 |
| Astellas Pharma US | Meals · 2025-03-14 | Izervay | $35 |
| Genentech USA | Meals · 2025-02-20 | Vabysmo | $35 |
| Apellis Pharmaceuticals | Meals · 2025-02-14 | Syfovre | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-02-11 | Eylea Hd | $37 |
| Apellis Pharmaceuticals | Meals · 2025-02-07 | Syfovre | $32 |
| Astellas Pharma US | Meals · 2025-02-05 | Izervay | $33 |
| Genentech USA | Meals · 2025-01-16 | Susvimo | $34 |
| Astellas Pharma US | Meals · 2025-01-08 | Izervay | $27 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,620
| Astellas Pharma US | Izervay | $485 | 13 payments
|
| Genentech USA | Vabysmo | $285 | 9 payments
|
| Apellis Pharmaceuticals | Syfovre | $169 | 10 payments
|
| Mallinckrodt Hospital Products | Acthar | $140 | 1 payment
|
| EyePoint Pharmaceuticals US | None | $125 | 1 payment
|
| Pfizer | Tivdak | $125 | 1 payment
|
| Abbvie | Ozurdex | $107 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea Hd | $102 | 3 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $59 | 2 payments
|
| Harrow Eye | Iheezo | $23 | 1 payment
|
2023: $1,593
| Carl Zeiss Meditec USA | Lumera 700 | $360 | 1 payment
|
| Astellas Pharma US | None | $277 | 7 payments
|
| Genentech USA | Vabysmo | $273 | 9 payments
|
| Apellis Pharmaceuticals | Syfovre | $193 | 4 payments
|
| Alcon Vision | Ngenuity | $140 | 1 payment
|
| Biogen | None | $100 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $96 | 3 payments
|
| AbbVie | Ozurdex | $62 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $30 | 1 payment
|
| Harrow Eye | Iheezo | $22 | 1 payment
|
| Alimera Sciences | Yutiq | $21 | 1 payment
|
| Coherus Biosciences | Cimerli | $18 | 1 payment
|
2022: $663
| Genentech USA | Lucentis | $251 | 5 payments
|
| Alcon Vision | Ngenuity | $140 | 1 payment
|
| Apellis Pharmaceuticals | None | $124 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $84 | 3 payments
|
| Regeneron Healthcare Solutions | Eylea | $26 | 1 payment
|
| EyePoint Pharmaceuticals US | Yutiq | $22 | 1 payment
|
| Biogen | None | $16 | 1 payment
|
2021: $353
| Genentech USA | Lucentis | $184 | 5 payments
|
| Allergan | Ozurdex | $130 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $40 | 2 payments
|
2020: $315
| Alcon Vision | Constellation | $141 | 1 payment
|
| Alimera Sciences | Iluvien | $88 | 4 payments
|
| Genentech USA | Lucentis | $48 | 2 payments
|
| Optos | P200dtx | $39 | 2 payments
|
2019: $742
| Novartis Pharmaceuticals | Beovu | $181 | 7 payments
|
| AbbVie | Humira | $125 | 1 payment
|
| Akcea Therapeutics | Tegsedi | $125 | 1 payment
|
| Shire North American Group | Xiidra | $91 | 1 payment
|
| Alcon Vision | Constellation | $61 | 1 payment
|
| Alimera Sciences | Iluvien | $59 | 3 payments
|
| Genentech | Lucentis | $51 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $32 | 1 payment
|
| Genentech USA | Lucentis | $17 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1265606461
- Licence
- CA A126226California A126226: Current · expires 2027-05-31
- Trained
- University of Wisconsin School of Medicine, 2007
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 3395 S Bascom Ave, Suite 140, Campbell, CA, 95008
- NPI first listed
- 2008-04-17
- NPI last updated
- 2013-08-06
This is when the NPI record was last certified, not a medical board exam.